CN106282113A - 一种利用无血清培养基通过转分化获得神经细胞的方法 - Google Patents
一种利用无血清培养基通过转分化获得神经细胞的方法 Download PDFInfo
- Publication number
- CN106282113A CN106282113A CN201510289740.6A CN201510289740A CN106282113A CN 106282113 A CN106282113 A CN 106282113A CN 201510289740 A CN201510289740 A CN 201510289740A CN 106282113 A CN106282113 A CN 106282113A
- Authority
- CN
- China
- Prior art keywords
- cell
- serum
- medium
- neurocyte
- free medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012679 serum free medium Substances 0.000 title claims abstract description 46
- 238000000034 method Methods 0.000 title claims abstract description 38
- 210000001082 somatic cell Anatomy 0.000 claims abstract description 24
- 239000007640 basal medium Substances 0.000 claims abstract description 22
- 210000004504 adult stem cell Anatomy 0.000 claims abstract description 20
- 239000000654 additive Substances 0.000 claims abstract description 16
- 230000000996 additive effect Effects 0.000 claims abstract description 16
- 210000002966 serum Anatomy 0.000 claims abstract description 16
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims abstract description 14
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims abstract description 13
- 102000013275 Somatomedins Human genes 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 102
- 239000001963 growth medium Substances 0.000 claims description 33
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 20
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 19
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 19
- 210000002950 fibroblast Anatomy 0.000 claims description 19
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 17
- 210000000130 stem cell Anatomy 0.000 claims description 16
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 15
- 241000699670 Mus sp. Species 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 10
- 229930003268 Vitamin C Natural products 0.000 claims description 10
- 238000010166 immunofluorescence Methods 0.000 claims description 10
- 235000019154 vitamin C Nutrition 0.000 claims description 10
- 239000011718 vitamin C Substances 0.000 claims description 10
- 230000006698 induction Effects 0.000 claims description 8
- 239000002609 medium Substances 0.000 claims description 7
- 230000010261 cell growth Effects 0.000 claims description 6
- 239000006147 Glasgow's Minimal Essential Medium Substances 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 5
- 239000007758 minimum essential medium Substances 0.000 claims description 5
- 210000005036 nerve Anatomy 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 4
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 claims description 3
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 claims description 3
- 102100021118 Microtubule-associated protein 2 Human genes 0.000 claims description 3
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 3
- 238000012549 training Methods 0.000 claims description 3
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 claims description 2
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 claims description 2
- 102100038126 Tenascin Human genes 0.000 claims description 2
- 108010008125 Tenascin Proteins 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 229940054269 sodium pyruvate Drugs 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 11
- 239000004017 serum-free culture medium Substances 0.000 abstract description 2
- 230000002103 transcriptional effect Effects 0.000 abstract description 2
- 210000001178 neural stem cell Anatomy 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 210000001161 mammalian embryo Anatomy 0.000 description 12
- 230000004069 differentiation Effects 0.000 description 10
- 208000015122 neurodegenerative disease Diseases 0.000 description 9
- 210000002569 neuron Anatomy 0.000 description 9
- 238000005138 cryopreservation Methods 0.000 description 7
- 210000001671 embryonic stem cell Anatomy 0.000 description 7
- 230000004770 neurodegeneration Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 208000032612 Glial tumor Diseases 0.000 description 6
- 206010018338 Glioma Diseases 0.000 description 6
- 239000006143 cell culture medium Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 108010082117 matrigel Proteins 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 108010063312 Metalloproteins Proteins 0.000 description 3
- 102000010750 Metalloproteins Human genes 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 210000001778 pluripotent stem cell Anatomy 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 208000020431 spinal cord injury Diseases 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000006727 cell loss Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000005155 neural progenitor cell Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229940124596 AChE inhibitor Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- -1 F12 Compound Chemical class 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 101150009249 MAP2 gene Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000002718 aborted fetus Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000625 blastula Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000019628 coolness Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 210000002304 esc Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000002266 hair cells auditory Anatomy 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000004336 spermatogonium Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Abstract
Description
N2 | B27 | bFGF | EGF | 维生素C | |
最优化 | 1% | 0% | 20ng/ml | 0ng/ml | 50μg/ml |
1 | 0% | 2% | 20ng/ml | 0ng/ml | 50μg/ml |
2 | 1% | 1% | 20ng/ml | 0ng/ml | 50μg/ml |
3 | 1% | 0% | 0ng/ml | 20ng/ml | 50μg/ml |
4 | 1% | 0% | 10ng/ml | 20ng/ml | 50μg/ml |
5 | 1% | 0% | 20ng/ml | 0ng/ml | 10μg/ml |
6 | 1% | 0% | 20ng/ml | 0ng/ml | 20μg/ml |
7 | 1% | 0% | 20ng/ml | 0ng/ml | 100μg/ml |
8 | 1% | 0% | 20ng/ml | 0ng/ml | 200μg/ml |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510289740.6A CN106282113B (zh) | 2015-05-29 | 2015-05-29 | 一种利用无血清培养基通过转分化获得神经细胞的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510289740.6A CN106282113B (zh) | 2015-05-29 | 2015-05-29 | 一种利用无血清培养基通过转分化获得神经细胞的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106282113A true CN106282113A (zh) | 2017-01-04 |
CN106282113B CN106282113B (zh) | 2020-01-03 |
Family
ID=57655378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510289740.6A Active CN106282113B (zh) | 2015-05-29 | 2015-05-29 | 一种利用无血清培养基通过转分化获得神经细胞的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106282113B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107151656A (zh) * | 2017-05-10 | 2017-09-12 | 中国科学院广州生物医药与健康研究院 | 一种提高体细胞向神经细胞转分化效率的方法 |
CN107254443A (zh) * | 2017-07-28 | 2017-10-17 | 广州赛莱拉干细胞科技股份有限公司 | 一种促进骨髓间充质干细胞向神经元分化的诱导培养基和诱导方法 |
CN110343660A (zh) * | 2018-04-08 | 2019-10-18 | 生物角(厦门)科技有限公司 | 一种间充质干细胞无血清培养基组合物 |
CN113774023A (zh) * | 2021-09-28 | 2021-12-10 | 中国食品药品检定研究院 | 人诱导多能干细胞诱导分化神经细胞评价模型的构建及其评价药物神经毒性的用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102952778A (zh) * | 2011-08-29 | 2013-03-06 | 北京清美联创干细胞科技有限公司 | 一种用吡嗪类小分子化合物诱导干细胞分化的方法 |
CN104004713A (zh) * | 2014-05-14 | 2014-08-27 | 安沂华 | 脐带间充质干细胞诱导培养为神经细胞的方法 |
CN104031882A (zh) * | 2014-06-20 | 2014-09-10 | 上海安集协康生物技术有限公司 | 人神经干细胞体外定向诱导分化为多巴胺能神经元的方法 |
-
2015
- 2015-05-29 CN CN201510289740.6A patent/CN106282113B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102952778A (zh) * | 2011-08-29 | 2013-03-06 | 北京清美联创干细胞科技有限公司 | 一种用吡嗪类小分子化合物诱导干细胞分化的方法 |
CN104004713A (zh) * | 2014-05-14 | 2014-08-27 | 安沂华 | 脐带间充质干细胞诱导培养为神经细胞的方法 |
CN104031882A (zh) * | 2014-06-20 | 2014-09-10 | 上海安集协康生物技术有限公司 | 人神经干细胞体外定向诱导分化为多巴胺能神经元的方法 |
Non-Patent Citations (2)
Title |
---|
ZHANG X ET AL.: "Adult human olfactory neural progenitors cultured in defined medium.", 《EXP NEUROL》 * |
杨丽红: "VEGF转染对MSCs向神经细胞诱导分化的影响", 《中华神经外科疾病研究杂志》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107151656A (zh) * | 2017-05-10 | 2017-09-12 | 中国科学院广州生物医药与健康研究院 | 一种提高体细胞向神经细胞转分化效率的方法 |
CN107254443A (zh) * | 2017-07-28 | 2017-10-17 | 广州赛莱拉干细胞科技股份有限公司 | 一种促进骨髓间充质干细胞向神经元分化的诱导培养基和诱导方法 |
CN107254443B (zh) * | 2017-07-28 | 2020-03-13 | 广州赛莱拉干细胞科技股份有限公司 | 一种促进骨髓间充质干细胞向神经元分化的诱导培养基和诱导方法 |
CN110343660A (zh) * | 2018-04-08 | 2019-10-18 | 生物角(厦门)科技有限公司 | 一种间充质干细胞无血清培养基组合物 |
CN113774023A (zh) * | 2021-09-28 | 2021-12-10 | 中国食品药品检定研究院 | 人诱导多能干细胞诱导分化神经细胞评价模型的构建及其评价药物神经毒性的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN106282113B (zh) | 2020-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lancaster et al. | Organogenesis in a dish: modeling development and disease using organoid technologies | |
CN103396993B (zh) | 衍生自灵长类胚胎干细胞的用于脊髓损伤的再髓鞘化和治疗的少突胶质细胞 | |
Sharma et al. | Stem cell culture engineering–process scale up and beyond | |
Quattrocelli et al. | Mouse and human mesoangioblasts: isolation and characterization from adult skeletal muscles | |
CN101748096A (zh) | 亚全能干细胞、其制备方法及其用途 | |
CN105745321A (zh) | 用于产生工程化心肌(ehm)的方法 | |
CN110484506B (zh) | 胶质母细胞瘤类器官模型的构建方法和应用 | |
CN105861428B (zh) | 一种诱导成纤维细胞转分化为心肌细胞的诱导培养基及其应用 | |
CN102191221A (zh) | 一种能无限自我更新的神经干细胞、其制备方法及其用途 | |
CN106282113A (zh) | 一种利用无血清培养基通过转分化获得神经细胞的方法 | |
WO2017097007A1 (zh) | 分化培养基及其在制备神经干细胞中的用途 | |
RU2433172C2 (ru) | Способ получения гомогенной популяции стволовых клеток и ее применение | |
An et al. | Effect of rat Schwann cell secretion on proliferation and differentiation of human neural stem cells | |
CN105754935B (zh) | 一种诱导成纤维细胞转分化为脂肪细胞的诱导培养基及其应用 | |
CN104845932A (zh) | 淫羊藿苷的新用途 | |
CN109266610A (zh) | 一种促进间充质干细胞分化为神经元的方法 | |
Dai et al. | The human skin-derived precursors for regenerative medicine: current state, challenges, and perspectives | |
CN106244548A (zh) | 木犀草素在诱导间充质干细胞向神经细胞定向分化中的用途 | |
CN111344392B (zh) | 一种细胞诱导的方法 | |
Otify et al. | Transdifferentiation of bone marrow mesenchymal stem cells into neural cells via cerebrospinal fluid | |
CN106350490B (zh) | 利用无血清培养基从成纤维细胞中获得神经细胞的方法 | |
Chen et al. | Trophic factor induction of human umbilical cord blood cells in vitro and in vivo | |
CN102741398B (zh) | 从干细胞生成神经细胞的方法、神经细胞及其应用 | |
CN105087475B (zh) | 一种细胞培养液及其应用以及诱导牙髓干细胞向神经样细胞分化的方法 | |
US20230076688A1 (en) | Method for preparing induced pluripotent stem cell line from mesenchymal stem cells, and cell line obtained thereby |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240229 Address after: Room 104, Building 2, No. 198 Kaiyuan Avenue, Huangpu District, Guangzhou City, Guangdong Province, 510700 Patentee after: Zhongke Meisi Stem Cell Regenerative Medical Technology (Guangzhou) Co.,Ltd. Country or region after: China Address before: 510530 open source Avenue 190, Science City, Luogang District, Guangzhou, Guangdong. Patentee before: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES Country or region before: China |